Nivolumab with temozolomide and radiotherapy for newly diagnosed glioblastoma with MGMT methylation [ID1582]
Discontinued
Reference number: GID-TA10495
The Department for Health and Social Care has asked NICE to conduct an appraisal of nivolumab with temozolomide and radiotherapy for newly diagnosed glioblastoma with MGMT methylation.
Please note that following on from advice received from the company this appraisal has been scheduled back into the work programme.
We now anticipate that the appraisal will begin during late June 2020 when we will write to you about how you can get involved.